DESIREE FRYE: Open Payments
NPI 1073634028 · SHERMAN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,738 in 83 payments from 22 companies in 2025. Trend: 2023 $1,302 · 2024 $1,698 · 2025 $1,738
Food & beverage: $1,738
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $280 |
| ABBVIE INC. | 15 | $271 |
| Regeneron Healthcare Solutions, Inc. | 6 | $212 |
| Lilly USA, LLC | 5 | $97 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $93 |
| Janssen Biotech, Inc. | 5 | $93 |
| GENZYME CORPORATION | 4 | $89 |
| Ardelyx, Inc. | 5 | $87 |
| Celltrion USA Inc. | 5 | $84 |
| Phathom Pharmaceuticals, Inc. | 6 | $83 |
Products named: DUPIXENT, ENTYVIO, RINVOQ, OMVOH, XIFAXAN, TREMFYA, IBSRELA, VEGZELMA.
Industry payments across TX — which companies pay providers there.
